(MedPage Today) — The FDA approved oral rilzabrutinib (Wayrilz) for treating persistent or chronic immune thrombocytopenia (ITP), the agency announced on Tuesday.
As the first Bruton’s tyrosine kinase (BTK) inhibitor for ITP, the indication stipulates…
Source link : https://www.medpagetoday.com/hematologyoncology/hematology/117263
Author :
Publish date : 2025-09-02 17:14:00
Copyright for syndicated content belongs to the linked Source.
